Results 41 to 50 of about 53,092 (237)
Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution
, 2022 Hepatology, EarlyView.
Ralf Weiskirchen
wiley +1 more source
Src kinase as a potential therapeutic target in non‐alcoholic and alcoholic steatohepatitis
Clinical and Translational Discovery, 2022 Non‐alcoholic steatohepatitis (NASH) and alcohol‐associated steatohepatitis (ASH) are the major cause of liver‐related mortality with limited therapeutic options available.
Dhadhang Wahyu Kurniawan +13 more
doaj +1 more source
Annals of Hepatology, 2016 Multiple genetic and environmental factors interact to determine an individual’s predisposition to non-alcoholic fatty liver disease and its phenotypic characteristics. Association studies have found a number of alleles associated with the development of
Jane I. Grove +4 more
doaj +1 more source
Mìžnarodnij Endokrinologìčnij Žurnal, 2020 Background. The purpose of the study was to determine the probable effect of a complex of metformin, rosuvastatin, essential phospholipids, and quercetin on the clinical course of non-alcoholic steatohepatitis, diabetic kidney disease, type 2 diabetes ...
O.S. Khukhlina +2 more
doaj +1 more source
Non alcoholic steatohepatitis.
Le Journal medical libanais. The Lebanese medical journal, 2002 Abstract The term ‘non-alcoholic steatohepatitis' (NASH) was introduced in 1980 to define a condition that is histologically similar to alcoholic liver disease but in which alcohol has no part and that is most commonly associated with obesity and/or type 2 diabetes. The condition can lead to cirrhosis and hepatocellular cancer.
H, Zantout, K, Barada
+8 more sources
Pathohistological characteristics of steatohepatitis on needle biopsy sample from 100 patients [PDF]
Medicinski Podmladak, 2019 Introduction: Steatohepatitis is a form of fatty liver disease, in which there is a deposit of fat and steatosis which occurs in two forms: alcoholic and non-alcoholic fatty liver disease.
Milićević Anđela +2 more
doaj
Journal of Cachexia, Sarcopenia and Muscle, 2021 Background Non‐alcoholic fatty liver (NAFL) disease (NAFLD) is the most common chronic liver disease in the world. While most subjects have ‘inert’ NAFL, a subset will progress to non‐alcoholic steatohepatitis (NASH) and its life‐threatening ...
Maxime Nachit +7 more
doaj +1 more source
Evaluating the effect of γ‐oryzanol on MASLD pathology using a medaka fish model
FEBS Open Bio, EarlyView.This study explores a liver disease called MASLD, which is increasing worldwide and can lead to serious damage. Researchers used medaka fish instead of rodents to test a food compound, γ‐oryzanol. Fish fed this compound had less liver fat and healthier gut bacteria.
Yukako Ito +7 more
wiley +1 more source
Evaluation of liver stiffness measurement–based scores in liver transplantation recipients
Liver Transplantation, EarlyView., 2022 Abstract Combining bioclinical parameters with liver stiffness measurement (LSM) has improved the diagnostic performance of vibration‐controlled transient elastography (VCTE) for detection of advanced fibrosis in patients with chronic liver disease. However, this approach has not yet been tested in liver transplantation (LT) recipients.
Tamoore Arshad +11 more
wiley +1 more source
Frontiers in Physiology, 2020 AimThe pathogenesis of non-alcoholic fatty liver disease is currently unclear, however, lipid accumulation leading to endoplasmic reticulum stress appears to be pivotal in the process. At present, FOXO1 is known to be involved in NAFLD progression.
Hao-ran Ding +19 more
doaj +1 more source